# Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women

> **NCT03951402** · PHASE1 · COMPLETED · sponsor: **Grünenthal GmbH** · enrollment: 48 (actual)

## Conditions studied

- Prolonged QTc Interval
- Pharmacokinetic

## Interventions

- **DRUG:** 100 mg CG5503 (tapentadol hydrochloride) PR tablet
- **DRUG:** Placebo matching CG5503 PR tablet
- **DRUG:** Placebo matching moxifloxacin capsule
- **DRUG:** 400 mg Moxifloxacin tablet (overencapsulated)

## Key facts

- **NCT ID:** NCT03951402
- **Lead sponsor:** Grünenthal GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2003-08
- **Final completion:** 2003-08
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2019-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03951402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03951402, "Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03951402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*